Towards personalized computer simulation of breast cancer treatment: a multi-scale pharmacokinetic and pharmacodynamic model informed by multi-type patient data
X. Lai, O. Geier, T. Fleischer, O. Garred, E. F. Borgen, S. Funke, S. Kumar, M. E. Rognes, T. Seierstad, A.-L. Boerresen-Dale, V. N. Kristensen, O. Engebraaten, A. Kohn-Luque, A. Frigessi
Abstract
Mathematical modeling and simulation have emerged as a potentially powerful, time and cost effective approach to personalized cancer treatment. The usefulness of mechanistic models to disentangle complex multi-scale cancer processes such as treatment response has been widely acknowledged. However, a major barrier for multi-scale models to predict the outcomes of therapeutic regimens in a particular patient lies in their initialization and parameterization which need to reflect individual cancer characteristics accurately. In this study we use multi-type routinely acquired measurements on a single breast tumor, including histopathology, magnetic resonance imaging, and molecular profiling to personalize parts of a complex multi-scale model of breast cancer treated with chemotherapeutic and anti-angiogenic agents. We model the dynamics of drugs in tissue (pharmacokinetics) and the corresponding effects on their targets (pharmacodynamics). We developed a open-source computer program that simulates cross-sections of tumors under 12-week therapy regimes and use it to individually reproduce and elucidate treatment outcomes of four patients. For two of the tumors that did not respond to therapy, we used model simulations to suggest alternative regimes, depending on their individual characteristics, with improved outcomes. We found that more frequent doses of chemothereapy reduce tumor burden in a low proliferative tumor while lower doses of anti-angiogenic agents improve drug penetration in a poorly perfused tumor. In addition to bridge multi-type clinical data to shed light on individual treatment outcomes, our approach identified a few tumor-related aspects that need to be clinically portraited better to allow for future model-driven personalized cancer therapy.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Combining Mechanistic Models and Machine Learning for Personalized Chemotherapy and Surgery Sequencing in Breast Cancer
Cristian Axenie, Daria Kurz·bioRxiv·Jun 8, 2020
- Multiscale Modeling of Cancer
Kerri-Ann Norton, Meghan McCabe Pryor, Aleksander S. Popel·bioRxiv·Dec 15, 2015
- A multi-state model of chemoresistance to characterize phenotypic dynamics in breast cancer
Grant R. Howard, Kaitlyn E. Johnson, … Amy Brock·Scientific ReportsPeer-reviewed·Aug 7, 2018
- Modeling Breast Cancer Proliferation, Drug Synergies, and Alternating Therapies
Wei He, Diane M. Demas, … William T. Baumann·iSciencePeer-reviewed·Apr 23, 2023
- A phase-field model for non-small cell lung cancer under the effects of immunotherapy
A. Wagner, P. Schlicke, … B. Wohlmuth·bioRxiv·Mar 20, 2023
- A mathematical model for phenotypic heterogeneity in breast cancer with implications for therapeutic strategies
X. Li, D. Thirumalai·bioRxiv·Jun 4, 2021